Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:49:35.481Z.
Calculation as of: 2026-10-06T19:49:35.481Z.
Quote observation: 2026-10-06T19:45:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69c6abe1898d62982c9f5472fcc208679ef9964d1dbc89e7ebe68f1e3eabf120
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Protara Therapeutics, Inc.
Market Cap
$144.73M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.18M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$144.06M
Price/FCF Ratio
1.14
TTM Avg
4.90
3Y Avg
4.90
5Y Avg
4.90
Market Cap
$145.07M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$145.55M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.26M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.52M
Price/FCF Ratio
N/A
TTM Avg
16.84
3Y Avg
51.25
5Y Avg
40.66
Market Cap
$148.69M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | $144.73M | N/A | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.18M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $144.06M | 1.14 | 4.90 | 4.90 | 4.90 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $145.07M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $145.55M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.26M | N/A | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $142.10M | N/A | N/A | N/A | N/A |
| Voyager Therapeutics, Inc. (VYGR)vs › | $146.52M | N/A | 16.84 | 51.25 | 40.66 |
| ALX Oncology Holdings Inc. (ALXO)vs › | $148.69M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $146.28M | N/A | 55.06 | 55.06 | 55.06 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
